Resource: A Compendium of HLA-Type and Expression in Pediatric Cancer Models

Cancer immunotherapy has transformed cancer treatment by harnessing the immune system’s natural ability to recognize and eliminate tumor cells, offering an effective and less toxic alternative particularly suitable for pediatric patients. Advances such as immune checkpoint inhibitors targeting PD-1 and CTLA-4, successful adoptive cell therapies like CAR T-cell treatments, and innovative cancer vaccines have notably improved outcomes across various cancer types. Central to immunotherapy is antigen presentation, where tumor-derived peptides loaded onto the Major Histocompatibility Complex molecules facilitate immune recognition. Precise HLA typing is crucial, especially in pediatric cancer research, where cell lines serve as essential preclinical models. The Childhood Cancer Model Atlas (CCMA) initiative provides comprehensive profiling, including HLA typing and neoantigen predictions for 287 cancer cell lines. This publicly accessible resource enables researchers to better understand immune-cancer interactions, advance personalized immunotherapies, and develop targeted, less toxic treatments specifically beneficial for children with cancer.